391 related articles for article (PubMed ID: 26916138)
1. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
2. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
3. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
4. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
5. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
Altzerinakou MA; Collette L; Paoletti X
J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
[TBL] [Abstract][Full Text] [Related]
6. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
[TBL] [Abstract][Full Text] [Related]
9. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.
Paoletti X; Le Tourneau C; Verweij J; Siu LL; Seymour L; Postel-Vinay S; Collette L; Rizzo E; Ivy P; Olmos D; Massard C; Lacombe D; Kaye SB; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2050-6. PubMed ID: 24928189
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
Le Tourneau C; Razak AR; Gan HK; Pop S; Diéras V; Tresca P; Paoletti X
Eur J Cancer; 2011 Jul; 47(10):1468-75. PubMed ID: 21482105
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
12. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
Townsley CA; Pond GR; Oza AM; Hirte HW; Winquist E; Goss G; Degendorfer P; Moore MJ; Siu LL
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2141-9. PubMed ID: 16609027
[TBL] [Abstract][Full Text] [Related]
14. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
15. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
16. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell M; Chow K; Sherwin B; Stayner LA; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A
Eur J Cancer; 2019 Jan; 107():1-7. PubMed ID: 30529898
[TBL] [Abstract][Full Text] [Related]
17. Determinants of the recommended phase 2 dose of molecular targeted agents.
Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
[TBL] [Abstract][Full Text] [Related]
18. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
19. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
